Medical Device News Magazine

ScreenPoint Medical Announces its New International Medical Advisory Board

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

ScreenPoint Medical, the company that developed the world leading Transpara® AI breast care system, today announced the launch of its new Medical Advisory Board (MAB) comprised of distinguished leaders in breast radiology from both sides of the Atlantic.

The MAB will help the company better understand the external medical and imaging environment, in particular the junction between imaging, breast AI, and cancer detection.  Additionally, we look forward to guidance on both existing products, those under development and future unmet market needs. Transpara Breast AI, which is now in daily use across the United States and in more than 30 other countries worldwide, has received endorsement from more peer reviewed scientific papers than any other breast AI product.

The new MAB brings together a unique team of renowned experts in the field who will have a continuing influence on the development of Transpara internationally.

“We are thrilled that such respected professionals have decided to join our Medical Advisory Board, “said Mark Koeniguer, CEO of ScreenPoint Medical. “Together, they bring an unparalleled wealth of experience to help guide us to the next level of development, and to ensure we can bring high impact solutions to clinicians while benefiting patients in our joint fight against breast cancer.”

The members of the new ScreenPoint Medical Advisory Board are:

  • Dr. Jennifer Harvey is Professor and Chair at the University of Rochester Department of Imaging Sciences. Harvey is an international expert in breast imaging and the early detection of breast cancer. Previously, she was on faculty at the University of Virginia for 26 years, leading its Division of Breast Imaging, Breast Cancer Program, and serving as vice-chair for Education and Faculty Development. Dr. Harvey’s primary research interest is mammographic breast density and the association with breast cancer risk.
  • Laurie Margolies, MD, Director of Breast Imaging at Mount Sinai Health System
    Laurie Margolies, MD, Director of Breast Imaging at Mount Sinai Health System

    Laurie Margolies, MD, Director of Breast Imaging at Mount Sinai Health System, an American College of Radiology fellow and past-President of the New York Breast Imaging Society.  Dr. Margolies received her medical degree from Yale School of Medicine and has been in practice for more than 20 years.  Her research interests include health care disparities, breast MRI, breast density and digital breast tomosynthesis. Dr. Margolies is an uncompensated consultant for ScreenPoint Medical.

  • Dr Ritse Mann, Breast and Interventional radiologist at the Radboud University Medical Center
    Dr Ritse Mann, Breast and Interventional radiologist at the Radboud University Medical Center

    Dr. Ritse Mann is a breast and interventional radiologist at the Radboud University Medical Center in Nijmegen and the Netherlands Cancer Institute in Amsterdam and is leading clinical breast imaging research at both institutions. His areas of interest include breast cancer screening, breast MRI, minimal invasive therapy and the use of artificial intelligence for screening, diagnosis and therapy selection of breast cancer. Dr. Mann is a member of the executive board of the European society of breast imaging (EUSOBI) since 2015 and  chairing its scientific committee and the  program planning committee of the annual meeting.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”